JUN-2026
Recent research in inflammatory bowel disease (IBD) highlights significant advances in disease prediction, monitoring, treatment, and long-term management. Studies have shown a potential link between IBD and cognitive decline, emphasizing the broader impact of chronic inflammation beyond the gut. Intestinal ultrasound is emerging as a valuable tool for identifying patients at risk of relapse even after endoscopic healing. Precision nutrition approaches are enabling more personalized dietary interventions for disease prevention and management. Genetic risk profiling has demonstrated the ability to predict disease severity, treatment requirements, and surgical outcomes. Evidence also supports the use of structured IBD care pathways to reduce healthcare costs while maintaining quality of care. Additionally, a first-in-human trial of Faecalibacterium prausnitzii EXL01 has shown promising safety and therapeutic potential as a novel microbiome-based treatment for Crohn’s disease.
Inflammatory Bowel Disease and Cognitive Decline: Evidence from Clinical and Preclinical Research
This systematic review examines the relationship between inflammatory bowel disease (IBD) and cognitive impairment, including deficits in memory, attention, and executive function. Analyzing 66 studies comprising population-based, genetic, and preclinical research, the review highlights that chronic inflammation, active disease, psychological stress, and gut–brain axis disturbances may contribute to cognitive decline in individuals with IBD. While findings across studies remain heterogeneous, the overall evidence suggests a potential association between IBD and impaired cognitive performance. Importantly, some therapeutic interventions for IBD appear to reduce the risk or severity of cognitive impairment, underscoring the importance of effective disease management. These findings emphasize the need for greater awareness of cognitive health in IBD care and future research into targeted preventive strategies.
Intestinal Ultrasound Enhances Relapse Prediction in Ulcerative Colitis
Recent evidence highlights the value of intestinal ultrasound (IUS) in assessing transmural healing (TH) and predicting relapse risk in ulcerative colitis (UC). TH, defined by a bowel wall thickness of less than 3 mm, was found to be a stronger predictor of sustained remission than endoscopic healing (EH) alone. As a non-invasive bedside tool, IUS enables clinicians to evaluate disease activity beyond the mucosal surface, offering additional prognostic insights. The study emphasizes that TH and EH are complementary treatment targets rather than competing measures. Particularly in patients with a Mayo Endoscopic Subscore of 1, IUS can help guide treatment decisions by identifying residual bowel wall inflammation. Integrating IUS into routine monitoring may support more personalized and effective long-term UC management
Precision Nutrition: A Personalized Approach to Preventing and Managing Inflammatory Bowel Disease
As the global burden of inflammatory bowel disease (IBD) continues to rise alongside dietary changes linked to industrialization, precision nutrition is gaining attention as a tailored strategy for disease prevention and management. This review highlights how individualized dietary recommendations, based on factors such as demographics, disease characteristics, and multiomics profiles, can improve patient outcomes. The authors propose a stepwise framework encompassing phenotype-based, omics-based, and integrated precision nutrition approaches to address variations in dietary responses among individuals. Advances in biomarker discovery, large-scale multiomics research, and artificial intelligence are accelerating the development and implementation of personalized nutrition strategies. This comprehensive framework offers a pathway toward more targeted, effective, and patient-centered nutritional interventions in IBD care and prevention.
Structured IBD Care Pathway Improves Value While Reducing Healthcare Costs
The multicentre IBD Value Study demonstrates that implementing an advanced therapy care pathway (ACP) for inflammatory bowel disease (IBD) can significantly reduce healthcare costs without compromising patient outcomes. Conducted across six intervention hospitals and two control hospitals, the study evaluated costs, quality of life, and disease control before and after ACP implementation. Results showed a substantial reduction in per-patient healthcare costs in hospitals adopting the ACP, generating average savings of nearly €1,934 per patient compared with controls. Importantly, quality-adjusted life years (QALYs) and disease control remained stable, indicating that cost savings were achieved without affecting clinical effectiveness or patient well-being. These findings support the adoption of standardized care pathways as a cost-effective strategy to enhance value-based IBD management.
Higher Genetic Risk Linked to More Severe Disease Progression in Inflammatory Bowel Disease
A large nationwide Danish cohort study found that genetic susceptibility to inflammatory bowel disease (IBD) is strongly associated with disease severity and progression. Using polygenic scores (PGS) in patients with Crohn’s disease (CD) and ulcerative colitis (UC), researchers observed that individuals with higher genetic risk had increased inflammatory markers, lower hemoglobin levels, and a greater likelihood of severe disease outcomes. Patients in the highest PGS group faced significantly higher risks of major surgery and were more likely to require corticosteroids, immunomodulators, and biologic therapies. The findings suggest that genetic risk profiling may help identify patients at risk of aggressive disease early in their disease course, enabling more personalized treatment strategies and improved long-term management of IBD.
Novel Live Biotherapeutic Shows Promise for Maintaining Remission in Crohn’s Disease
A first-in-human clinical trial has demonstrated the safety and feasibility of Faecalibacterium prausnitzii EXL01, a novel live biotherapeutic candidate for Crohn’s disease (CD). The study enrolled patients with mild to moderate CD who had achieved clinical response or remission following corticosteroid treatment. EXL01 was well tolerated, with no treatment-related adverse events reported. Preclinical studies showed strong anti-inflammatory effects, while human data revealed beneficial changes in intestinal gene expression, including modulation of immune-related pathways and enhanced energy metabolism. Although two participants experienced disease flare-ups, most maintained remission during the study period. These findings provide early proof-of-concept for F. prausnitzii EXL01 as a first-in-class microbiome-based therapy, supporting further research into its role in long-term Crohn’s disease management.